Allison Krebs Bensch
Allison Krebs-Bensch, a graduate of Vanderbilt University, has been intrinsically involved in her family’s pharmaceutical business, US Pharmaceutical Corporation, since graduating. Rolling up her sleeves, Allison dove into learning every aspect of the business from Sales to R & D, before eventually taking over the responsibilities of CEO.
Allison’s accomplishments include being listed as an inventor on patents for Improved Toleration of Iron Supplement Compositions. Additionally, she has developed, progressive & pending, patented formulations utilizing new probiotic strains for various applications of use. Most recently, she has co-founded and is CEO of a start-up probiotic skin care company, BeBe and Bella. This company specializes in delivering probiotics and their fermented filtrates, both orally and topically, for improved natural beauty. As co-founder, Allison has been invited to be a Speaker at several symposiums related to the science behind probiotics.
David H. Crean
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firms life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. Davids transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.
Dr. Creans pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOMs Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.
Emma Taylor
Dr. Emma Taylor the CEO and co-founder of Naked Biome, a microbiome therapeutics company, focused in acne She is a UCLA-trained and board certified Dermatologist and Dermatopathologist, and former assistant professor of Dermatology and Dermatopathology at UCLA, where she c0-founded Naked Biome. She is also an inventor of 2 published patents, has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 book chapters.
Richard Andrews
Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College.
Jim Perkins
Sergio Radovcic
14x Entrepreneur, Former CEO @Inmoo, CTO @HealthiestYou, CEO @FitFul, 14x Ironman Finisher, 3x Badwater 135, Father of 3.
